Corrigendum to: Techno-economic analysis of a transient plant-based platform for monoclonal antibody production (mAbs, 8, (1456-1466), 10.1080/19420862.2016.1227901);Techno-economic analysis of a transient plant-based platform for monoclonal antibody production

mAbs

Volumn 8, Issue 8, 2016, Pages 1456-1466

  Nandi, Somen ^a   Kwong, Aaron T ^a,b   Holtz, Barry R ^c   Erwin, Robert L ^c   Marcel, Sylvain ^c   McDonald, Karen A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California Davis   (United States)

^c iBio CMO LLC   (United States)

Author keywords

Monoclonal antibodies; plant made pharmaceuticals; techno economic analysis

Indexed keywords

MONOCLONAL ANTIBODY;

AFFINITY CHROMATOGRAPHY; AGROBACTERIUM TUMEFACIENS; ANION EXCHANGE CHROMATOGRAPHY; ANTIBODY PRODUCTION; CHO CELL LINE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; INTELLECTUAL ASSESSMENT; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; PROCESS OPTIMIZATION; SENSITIVITY ANALYSIS; BIOREACTOR; BIOSYNTHESIS; BIOTECHNOLOGY; ECONOMICS; HUMAN; PROCEDURES; TOBACCO; TRANSGENIC PLANT;

ANTIBODIES, MONOCLONAL; BIOREACTORS; BIOTECHNOLOGY; HUMANS; PLANTS, GENETICALLY MODIFIED; TOBACCO;

EID: 84989247256     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1270655     Document Type: Erratum

References (31)

1. D.M.Ecker, S.D.Jones, H.L.Levine. The therapeutic monoclonal antibody market. MAbs 2015; 7:9-14; PMID:25529996; http://dx.doi.org/10.4161/19420862.2015.989042
2. J.Highsmith. Biologic Therapeutic Drugs:Technologies and Global Markets. Wellesley, MA:BCC Research, Jan 2015.
3. B.De Muynck, C.Navarre, M.Boutry. Production of antibodies in plants:status after twenty years. Plant Biotechnol J 2010; 8:529-63; PMID:20132515; http://dx.doi.org/10.1111/j.1467-7652.2009.00494.x
4. K.L.Wycoff. Secretory IgA antibodies from plants. Curr Pharm Des 2005; 11:2429-37; PMID:16026297; http://dx.doi.org/10.2174/1381612054367508
5. A.Loos, C.Gruber, F.Altmann, U.Mehofer, F.Hensel, M.Grandits, C.Oostenbrink, G.Stadlmayr, P.G.Furtmüller, H.Steinkellner. Expression and glycoengineering of functionally active heteromultimeric IgM in plants. Proc Natl Acad Sci 2014; 111:6263-8; PMID:24706782; http://dx.doi.org/10.1073/pnas.1320544111
6. N.Landry, B.J.Ward, S.Trépanier, E.Montomoli, M.Dargis, G.Lapini, L.P.Vézina. Preclinical and clinical development of plant-made virus-like particle vaccine against Avian H5N1 influenza. PLoS One 2010; 5:e15559; PMID:21203523; http://dx.doi.org/10.1371/journal.pone.0015559
7. N.Scotti, E.P.Rybicki. Virus-like particles produced in plants as potential vaccines. Exp Rev Vaccines 2013; 12:211-24; PMID:23414411; http://dx.doi.org/10.1586/erv.12.147
8. J.L.Fox. First plant-made biologic approved. Nat Biotech 2012; 30:472; http://dx.doi.org/10.1038/nbt0612-472
9. M.Sack, A.Hofbauer, R.Fischer, E.Stoger. The increasing value of plant-made proteins. Curr Opin Biotechnol 2015; 32:163-70; PMID:25578557; http://dx.doi.org/10.1016/j.copbio.2014.12.008
10. A.Hiatt, R.Caffferkey, K.Bowdish. Production of antibodies in transgenic plants. Nature 1989; 342:76-8; PMID:2509938; http://dx.doi.org/10.1038/342076a0
11. M.H.Kumagai, T.H.Turpen, N.Weinzettl, G.della-Cioppa, A.M.Turpen, J.Donson, M.E.Hilf, G.L.Grantham, W.O.Dawson, T.P.Chow. Rapid, high-level expression of biologically active α-trichosanthin in transfected plants by an RNA viral vector. Proc Natl Acad Sci 1993; 90:427-30; PMID:8421670; http://dx.doi.org/10.1073/pnas.90.2.427
12. R.L.Erwin, L.K.Grill, G.P.Pogue, T.H.Turpen, M.H.Kumagai. Production of lysosomal enzymes in plants by transient expression. Patent 6,846,968, Jan 25, 2005.
13. A.K.Sharma, M.K.Sharma. Plants as bioreactors:Recent developments and emerging opportunities. Biotechnol Adv 2009; 27:811-32; PMID:19576278; http://dx.doi.org/10.1016/j.biotechadv.2009.06.004
14. S.B.Gelvin. Plant proteins involved in Agrobacterium-mediated genetic transformation. Annu Rev Phytopathol 2010; 48:45-68; PMID:20337518; http://dx.doi.org/10.1146/annurev-phyto-080508-081852
15. S.Marillonnet, A.Giritch, M.Gils, R.Kandzia, V.Klimyuk, Y.Gleba. In planta engineering of viral RNA replicons:Efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci 2004; 101:6852-7; PMID:15103020; http://dx.doi.org/10.1073/pnas.0400149101
16. G.Roy, S.Weisburg, S.Rabindran, V.Yusibov. A novel two-component Tobacco mosaic virus-based vector system for high-level expression of multiple therapeutic proteins including a human monoclonal antibody in plants. Virology 2010; 405:93-9; PMID:20673747; http://dx.doi.org/10.1016/j.virol.2010.05.016
17. B.R.Holtz, B.R.Berquist, L.D.Bennett, V.J.Kommineni, R.K.Munigunti, E.L.White, D.C.Wilkerson, K.Y.Wong, L.H.Ly, S.Marcel. Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. Plant Biotechnol J 2015; 13:1180-90; PMID:26387511; http://dx.doi.org/10.1111/pbi.12469
18. D.Tusé, T.Tu, K.A.McDonald. Manufacturing economics of plant-made biologics:case studies in therapeutic and industrial enzymes. Biomed Res Int 2014; 2014:256135; PMID:24977145; http://dx.doi.org/10.1155/2014/256135
19. D.R.Walwyn, S.M.Huddy, E.P.Rybicki. Techno-economic analysis of horseradish peroxidase production using a transient expression system in Nicotiana benthamiana. Appl Biochem Biotechnol 2015; 175:841-54; PMID:25344434; http://dx.doi.org/10.1007/s12010-014-1320-5
20. J.F.Buyel, R.Fischer. Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs. Biotechnol Bioeng 2012; 109:2575-88; PMID:22511291; http://dx.doi.org/10.1002/bit.24523
21. J.R.Birch, A.J.Racher. Antibody production. Adv Drug Delivery Rev 2006; 58:671-85; PMID:16822577; http://dx.doi.org/10.1016/j.addr.2005.12.006
22. S.S.Farid. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848:8-18; PMID:16899415; http://dx.doi.org/10.1016/j.jchromb.2006.07.037
23. J.Walther, R.Godawat, C.Hwang, Y.Abe, A.Sinclair, K.Konstantinov. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. J Biotechnol 2015; 213:3-12; PMID:26014522; http://dx.doi.org/10.1016/j.jbiotec.2015.05.010
24. L.R.Wilken, Z.L.Nikolov. Downstream processing of transgenic plant systems:protein recovery and purification strategies. In:A.Wang, S.Ma, eds. Molecular Farming in Plants:Recent Advances and Future Prospects. New York, NY:Springer, 2012; http://dx.doi.org/10.1007/978-94-007-2217-0_11
25. S.Nandi, D.Yalda, S.Lu, Z.Nikolov, R.Misaki, K.Fujiyama, N.Huang. Process development and economic evaluation of recombinant human lactoferrin expressed in rice grain. Transgenic Res 2005; 14:237-49; PMID:16145832; http://dx.doi.org/10.1007/s11248-004-8120-6
26. R.G.Werner. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol 2004; 113:171-82; PMID:15380655; http://dx.doi.org/10.1016/j.jbiotec.2004.04.036
27. A.Xenopoulos. A new, integrated, continuous purification process template for monoclonal antibodies:Process modeling and cost of goods studies. J Biotechnol 2015; 213:42-53; PMID:25959171; http://dx.doi.org/10.1016/j.jbiotec.2015.04.020
28. B.Kelley. Industrialization of mAb production technology:The bioprocessing industry at a crossroads. Mabs 2009; 1:443-52; PMID:20065641; http://dx.doi.org/10.4161/mabs.1.5.9448
29. D.Petrides, D.Carmichael, C.Siletti, A.Koulouris. Biopharmaceutical process optimization with simulation and scheduling tools. Bioengineering 2014; 1:154-87; http://dx.doi.org/10.3390/bioengineering1040154
30. J.K.Ma, P.M.Drake, P.Christou. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003; 4:794-805; PMID:14526375; http://dx.doi.org/10.1038/nrg1177
31. M.S.Peters, K.D.Timmerhaus, R.E.West. Plant design and economics for chemical engineers. New York, NY:McGraw Hill, 2003.